Xyratex Ltd. (NASDAQ: XRTX) jumped up 26.72% to end the day at $8.30 after the company announced better than expected preliminary revenue results for its third quarter, of 247 million dollars. The total traded volume was 1.09 million shares compared to total average daily volume of just 62K shares. The stock has already rallied over 5 times from its 52-week low of $1.55, touched in the month of January this year.

Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) soared $1.05 or 60.57% to $2.80 on volume of 15.76 million shares more than 15.50X than its daily total average volume on the news that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease. HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.

Geron Corporation ( NASDAQ: GERN) announced today that the company received a verbal notice from the FDA that Geron's Investigational New Drug (IND) submission for GRNOPC1, its cell therapy for spinal cord injury, has been placed on clinical hold. This is an order that the FDA issues to a company to delay a proposed trial or to suspend an ongoing investigation. As the company has not seen the reasons for the hold in writing via a letter, it is unable to comment specifically. The company said in the release that it has been in communications with the FDA for 4 years...

FRANKFURT, Feb 12 (Reuters) - European shares inched higher on Tuesday as gains in oils majors offset weaker financials after Credit Suisse's earnings and market talk of a large writedown at Dutch group ING ( nyse: IND - news - people ). Heavyweight

FRANKFURT, Feb 12 (Reuters) - European shares inched higher on Tuesday as gains in oils majors offset weaker financials after Credit Suisse's earnings and market talk of a large writedown at Dutch group ING ( nyse: IND - news - people ). Heavyweight

Wealth Daily Editor Steve Christ takes a look at top biotech stocks and the race for a cure.

Advanced Cell Technology, Inc. (Public, OTC:ACTC.OB) MiV Investments Inc. has initiated independent research coverage on Advanced Cell Technology Inc. (OTC:ACTC.OB), which is anticipating a filing of an investigational new drug (IND) application which takes on a 28B Age-related macular degeneration (AMD) market, with over 30 million people affected by the disease. The company expects to [...]

Xcellink International Inc. (XCEL), PolyMedix, Inc. (PYMX), and Dynamic Response Group, Inc. (DRGZ) were among today’s top OTC market movers. Xcellink International Inc. [[XCEL.OB]], a developer of advanced consumer-centric payment systems and methodologies, shares rose nearly 10 percent after announcing that it has built a prototype of its payment system on Research In Motion’s Blackberry software [...]

Yesterday, Geron Corp. (GERN) provided an update on its experimental candidate, GRNOPC1, which is currently under clinical hold. On Aug. 18, Geron suffered a setback when the US Food and Drug Administration (FDA) put its Investigational New Drug (IND) application for the product on hold. Earlier this year, the FDA cleared the company to begin clinical [...]

(GERN) Geron FDA Experimental Application on Hold

Novelos Therapeutics, Inc. ( OTCBB:NVLT) was established in 1996 to commercialize two promising oxidized glutathione-based compounds, NOV-002 and NOV-205, for the treatment of cancer and hepatitis. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were developed. NOV-002, the lead compound, is designed to act as a chemoprotectant and an immunomodulator. It is marketed in Russia by Pharma BAM under the trade name Glutoxim®, and has been administered to over 5,000 patients, demonstrating clinical efficacy and excellent safety. The U.S.-based Phase 1/2 clinical study of NOV-002 in combination with chemotherapy for lung cancer has been completed, with positive results. The FDA has agreed that advancing NOV-002 into a single pivotal Phase 3 study in advanced NSCLC is warranted, and this study is expected to commence in 2006. NOV-002 is also being developed to treat chemotherapy-resistant ovarian cancer and acute radiation injury. NOV-205, the second compound, is designed to act as a hepatoprotective agent with immunomodulating and antiviral activity. In Russian clinical studies in hepatitis B and C patients, NOV-205 greatly reduced or eliminated viral load and significantly improved liver function. Novelos plans to file an Investigational New Drug Application (IND) with the FDA for NOV-205 as monotherapy for hepatitis C by the end of 2005 and initiate a U.S.-based Phase 1/2 clinical study in early 2006.